Cite
Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia.
MLA
Helal, Christopher J., et al. “Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia.” Journal of Medicinal Chemistry, vol. 54, no. 13, July 2011, pp. 4536–47. EBSCOhost, https://doi.org/10.1021/jm2001508.
APA
Helal, C. J., Kang, Z., Hou, X., Pandit, J., Chappie, T. A., Humphrey, J. M., Marr, E. S., Fennell, K. F., Chenard, L. K., Fox, C., Schmidt, C. J., Williams, R. D., Chapin, D. S., Siuciak, J., Lebel, L., Menniti, F., Cianfrogna, J., Fonseca, K. R., Nelson, F. R., & OâConnor, R. (2011). Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia. Journal of Medicinal Chemistry, 54(13), 4536–4547. https://doi.org/10.1021/jm2001508
Chicago
Helal, Christopher J., Zhijun Kang, Xinjun Hou, Jayvardhan Pandit, Thomas A. Chappie, John M. Humphrey, Eric S. Marr, et al. 2011. “Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia.” Journal of Medicinal Chemistry 54 (13): 4536–47. doi:10.1021/jm2001508.